Hey Michelle,
I was surprised to see the relatively large difference in HPV vaccine rates between men and women. Certainly the initial FDA-approval status would have had a large impact on this difference, and possibly reflects an early understanding of the vaccine's potential use. In addition to your suggestions, I wonder if educational/awareness projects may encourage adherence to programs intended to achieve vaccination levels necessary to achieve herd immunity. I'm assuming that the incline in cancer incidence suggests that the current vaccination rate is too low. Another measure that may help would be to identify the communities that are suffering most from increased cancer incidence, and offer appropriate awareness, outreach, and clinical services to those groups.
I was surprised to see the relatively large difference in HPV vaccine rates between men and women. Certainly the initial FDA-approval status would have had a large impact on this difference, and possibly reflects an early understanding of the vaccine's potential use. In addition to your suggestions, I wonder if educational/awareness projects may encourage adherence to programs intended to achieve vaccination levels necessary to achieve herd immunity. I'm assuming that the incline in cancer incidence suggests that the current vaccination rate is too low. Another measure that may help would be to identify the communities that are suffering most from increased cancer incidence, and offer appropriate awareness, outreach, and clinical services to those groups.